

RECEIVED
JUN 02 2003
TECH CENTER 1800/2900



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Application Number	10/081,713
Filing Date	February 21, 2002
First Named Inventor	C. PLATA-SALAMAN et al.
Group Art Unit	1614
Examiner Name	William Jarvis
Attorney Docket Number	ORT-1583

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
PS	✓	STEIN, M.B., <i>Neurobiological Perspectives on Social Phobia: From Affiliation to Zoology</i> , Biol. Psychiatry, 1998, 44 (12), 1277-1285.	
PS	✓	NEWBURN, G., <i>Psychiatric Disorders Associated with Traumatic Brain Injury, Optimal Treatment</i> , CNS Drugs, 1998, 9 (6), 441-456.	
PS	✓	LIDBERG, L., et al., <i>Suicide Attempts and Impulse Control Disorder are Related to Low Cerebrospinal Fluid 5-HIAA in Mentally Disordered Violent Offenders</i> , Acta Psychiatr. Scand., 2000, 101 (5), 395-402.	
PS	✓	VAN AMERINGEN, M., et al., <i>Drugs in Development for Social Anxiety Disorder: More to Social Anxiety Than Meets the SSRi</i> , expert Opin. Invest. Drugs, 2000, 9 (10), 2215-2231.	
PS	✓	ZHUANG, S., et al., <i>Altered Emotional States in Knockout Mice Lacking 5-HT1A or 5-HT1B Receptors</i> , Neuropsychopharmacology, 1999, 21 (2S), 52S-60S.	
PS	✓	WATA, Y., et al., <i>Carbamazepine Augmentation of Clomipramine in the Treatment of Refractory Obsessive-Compulsive Disorder</i> [letter], J. Clinical Psychiatry, 2000, 61 (7), 528-529.	
PS	✓	HOLLANDER, E., <i>Managing Aggressive Behavior in Patients with Obsessive-Compulsive Disorder and Borderline Personality Disorder</i> , J. Clinical Psychiatry, 1999, 60 (Suppl), 1538-1544.	
PS	✓	CORA-LOCATELLI, G., et al., <i>Gabapentin Augmentation for Fluoxetine-Treated Patients with Obsessive-Compulsive Disorder</i> [letter], J. Clinical Psychiatry, 1998, 59 (9), 480-481.	
PS	✓	KOPOWITZ, L.E., et al., <i>Response of Obsessive Compulsive Disorder to Carbamazepine in Two Patients with Comorbid Epilepsy</i> , Annals of Clinical Psychiatry, 1997, 9 (3), 171-173.	
PS	✓	JEFFERSON, J.W., <i>Benzodiazepines and Anticonvulsants for Social Phobia (Social Anxiety Disorder)</i> , J. Clin. Psychiatry, 2001, 62 (Suppl. 1), 50-53.	
PS	✓	CONNOR, K.M., et al., <i>Social Phobia: Issues in Assessment and Management</i> , Epilepsia, 1999, 40 (Suppl 6), S60-65, Discussion S60-65.	
PS	✓	BRODSKY, L., et al., <i>Post Traumatic Stress Disorder: An Eclectic Approach</i> , International Journal of Psychosomatics, 1990, 37 (1-4), 89-95.	
PS	✓	ADAMEC, R., et al., <i>Effects of Baseline Anxiety on Response to Kindling of the Right Medial Amygdala</i> , Physiol. Behav., 2000, 70 (1/2), 67-80.	
PS	✓	FRIEDMAN, M.J., <i>What Might the Psychobiology of Posttraumatic Stress Disorder Teach Us About Future Approaches to Pharmacotherapy?</i> , J. clin. Psychiatry, 2000, 61 (Suppl. 7), 44-51.	
PS	✓	STAM, R., et al., <i>Long-lasting Stress Sensitisation</i> , Eur. J. Pharmacol., 2000, 406 (1-3), 217-224.	
PS	✓	SOUTHWICK, S.M., et al., <i>Role of Norepinephrine in the Pathophysiology and Treatment of Posttraumatic Stress Disorder</i> , Biol. Psychiatry, 1999, 46 (9), 1192-1204.	
PS	✓	HERTZBERG, M.A., et al., <i>A Preliminary Study of Lamotrigine for the Treatment of Posttraumatic Stress Disorder</i> , Biol. Psychiatry, 1999, 45, 1226-1229.	
PS	✓	DAVIDSON, J., <i>Biological Therapies for Posttraumatic Stress Disorder: An Overview</i> , J. Clinical Psychiatry, 1997, 58 (Suppl), 29-32.	
PS	✓	FRIEDMAN, M.J., <i>Drug Treatment for PTSD, Answers and Questions</i> , Annals of the New York Academy of Sciences, 1997 (JUN 21), 821, 359-371.	
PS	✓	FORD, N., <i>The Use of Anticonvulsants in Posttraumatic Stress Disorder: Case Study and Overview</i> , J. Traumatic Stress, 1996, 9 (4), 857-863.	
PS	✓	SUTHERLAND, S.M., et al., <i>Pharmacotherapy for Post-Traumatic Stress Disorder</i> , Psychiatric Clinics of North America, 1994, 17 (2), 409-423.	
PS	✓	KECK, P.E., et al., <i>Valproate and Carbamazepine in the Treatment of Panic and Posttraumatic Stress Disorders, Withdrawal States, and Behavioral Dyscontrol Syndromes</i> , J. OF CLINICAL Psychopharmacology, 1992, 12 (1 Suppl), 36S-41S.	
PS	✓	BERIGAN, T., et al., <i>Valproate as an Alternative in Post-Traumatic Stress Disorder: A Case Report</i> , Military Medicine, 1995, 160 (6) 318.	
PS	✓	BERLANT, J., <i>Topiramate in Chronic Civilian Posttraumatic Stress Disorder - An Open Label Study of a Novel Treatment</i> , International Society for Traumatic Stress Studies, Melbourne, Australia, 2000.	
PS	✓	BRANNON, N., et al., <i>Gabapentin Treatment for Posttraumatic Stress Disorder</i> , Canadian J. Psychiatry, 2000, 45 (1) 84.	
PS	✓	CLARK, R.D., et al., <i>Divalproex in Posttraumatic Stress Disorder: An Open-Label Clinical Trial</i> , J. Trauma. Stress, 1999, 12 (2) 395-401.	
PS	✓	FESLER, F.A., <i>Valproate in Combat-Related Posttraumatic Stress Disorder</i> , J. Clin. Psychiatry, 1991, 52 (9) 361-364.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

TECH CENTER 1600/2900

RECEIVED
JUN 9 2 2003

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



SUBMISSION UNDER MPEP 609 D Page 1 of 1	Application Number	10/081,713
	Filing Date	February 21, 2002
	First Named Inventor	C. PLATA-SALAMAN et al.
	Group Art Unit	1614
	Examiner Name	William Jarvis
	Attorney Docket Number	ORT-1583

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	U.S. Patent Document		Pages, Columns, Lines, where relevant passages or relevant figures appear
			Number	Kind Code ² (if known)	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	Foreign Patent Document			Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
			Office ³	Number ⁴	KindCode ⁵		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner 's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		International Search Report for Application No. PCT/US02/05423 dated July 17, 2002	

Examiner Signature	Date Considered
-----------------------	--------------------

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

TECH CENTER 1600/2900

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
This is a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet 2 of 2

Application Number	10/081,713
Filing Date	February 21, 2002
First Named Inventor	C. Plata-Salaman
Group Art Unit	1614
Examiner Name	W. Jarvis
Attorney Docket Number	ORT-1583

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

[illegible]

TECH CENTER 1-600/2900

JUL 25 2003

RECEIVED

Examiner
Signature

Phyllis Spivack

Date
Considered

9/10/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

JUN 11 2003

TECH CENTER 1600/2900



SUBMISSION UNDER MPEP 609 D Page 1 of 1	Application Number	10/081,713
	Filing Date	February 21, 2002
	First Named Inventor	C. Plata-Salaman
	Group Art Unit	1614
	Examiner Name	W. Jarvis
	Attorney Docket Number	ORT-1583

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	U.S. Patent Document		Pages, Columns, Lines, where relevant passages or relevant figures appear
			Number	Kind Code ² (if known)	
		Ortho-McNeil Pharmaceutical, Inc.	USSN 09/906,251 our docket no. ORT-1465		
		Ortho-McNeil Pharmaceutical, Inc.	USSN 10/681,501 our docket no. ORT-1577		
		Ortho-McNeil Pharmaceutical, Inc.	USSN 10/681,606 our docket no. ORT-1581		
		Ortho-McNeil Pharmaceutical, Inc.	USSN 10/192,973 our docket no. ORT-1642		
		Ortho-McNeil Pharmaceutical, Inc.	USSN 10/081,943 our docket no. ORT-1578		
		Ortho-McNeil Pharmaceutical, Inc.	USSN 10/193,600 our docket no. ORT-1641		
		Ortho-McNeil Pharmaceutical, Inc.	USSN 10/081,764 our docket no. ORT-1575		

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	Foreign Patent Document			Pages, Columns, Lines, where relevant passages or relevant figures appear	T ³
			Office ³	Number ⁴	Kind Code ⁵		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials [*]	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		International Search Report for Application No. PCT/US02/05423 dated July 17, 2002	

Examiner Signature	Date Considered
--------------------	-----------------

RECEIVED

JUL 25 2003